

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



三生制药
3SBIO INC.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1530)

(1) POSITIVE PROFIT ALERT; AND (2) CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG AS A RESULT OF CHANGE OF SECRETARIAL COMPANY

POSITIVE PROFIT ALERT

This announcement is made by 3SBio Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders (the “**Shareholders**”) and the potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group (prepared in accordance with International Financial Reporting Standards (IFRS)) for the year ended 31 December 2021 and the currently available information, it is expected that the net profit and the profit attributable to equity shareholders for the year ended 31 December 2021 will record an increase ranging from 100% to 120% and 90% to 110%, respectively, compared with those for the corresponding period of last year. Such increase was primarily attributable to, among other factors:

- (i) the significant growth in revenue and gross profit of the Group’s core products, namely, TPIAO, Mandi, Yisaipu, which have been successfully launched, achieved significant growth and continued to make substantial contributions to the Group’s profits and revenue; and
- (ii) the decrease in expenses mainly due to the completion of diabetes business divestment and decrease in donation expenses.

The Company is still in the process of finalising the annual results of the Group for the year ended 31 December 2021. The information contained in this announcement is only based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2021, which are subject to finalisation and other potential adjustments, if any, and have not been reviewed or confirmed by the auditors of the Group or the audit committee of the Board of the Company. Shareholders and potential investors of the Company should refer to the annual results announcement of the Group for the year ended 31 December 2021, which is expected to be published by the end of March 2022.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG AS A RESULT OF CHANGE OF SECRETARIAL COMPANY

Reference is made to the announcement of the Company dated 21 January 2022 in relation to, among others, the change of Company Secretary, Authorized Representative and Process Agent as a result of the Company's new engagement at its discretion of an external corporate services firm to provide general corporate and secretarial support services to the Company for efficiency.

The Board also announces that due to the above new engagement, the Company's principal place of business in Hong Kong will be changed to 5/F, Manulife Place, 348 Kwun Tong Road, Kowloon, Hong Kong with effect from 10 February 2022.

By order of the Board
3SBio Inc.
Dr. LOU Jing
Chairman

Shenyang, the PRC
7 February 2022

As at the date of this announcement, the Board comprises Dr. LOU Jing and Ms. SU Dongmei as executive Directors; Mr. HUANG Bin and Mr. TANG Ke as non-executive Directors; and Mr. PU Tianruo, Ms. YANG Hoi Ti Heidi and Mr. NG, Joo Yeow Gerry as independent non-executive Directors.